PACTR201804003334544Other未知
A randomized controlled trial of TCA 35% versus phenol 88% in treatment of alopecia areata
no sponsor0 个研究点目标入组 40 人开始时间: 2018年4月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 4 Year(s) 至 60 Year(s)（—）
- 性别
- All
入选标准
- •Subjects with multifocal patchy AA of the scalp (> 2 patches).
- •Both genders.
- •Age group > 4 years old.
排除标准
- •Any subject with any variant of AA other than the multifocal patchy variant.
- •Any subject with end-stage cicatrized AA.
- •Any subject who is currently experiencing significant spontaneous regrowth of terminal hair.
- •Any subject treated with a topical, intralesional or systemic agent likely to cause regrowth in AA within one month prior to enrollment in the study.
- •Any subject with a dermatological condition affecting the scalp other than AA: e.g. psoriasis, eczema.
- •Any subject with psychiatric illness or psychological state interfering with compliance or influencing the expectation of the patient.
研究者
相似试验
已完成
2 期
The evaluation of efficacy of TCA (TriChloroAcetic Acid) 33% in the treatment of lip fissure due to retinoidsip fissuring.Diseases of lipsIRCT201301169800N4Tehran University of Medical Sciences37
招募中
3 期
The effect of TCA (20%) trichloroacetic acid and topical combination of steroid and tretinoin in macular amyloidosisIRCT20180102038188N1Sabzevar University of Medical Sciences20
已完成
早期 1 期
Comparative study of topical TCA %50 and cultured autologous fibroblasts in the treatment of the atrophic scars of face.(Pilot Study)atrophic scar.Scar conditions and fibrosis of skinIRCT138902081159N2Isfahan University of Medical Sciences20
已完成
4 期
Comparison between subcision followed by 35% TCA versus subcision followed by microneedling in the treatment of acne scars: a prospective comparative study.Skin and Connective Tissue DiseasesPACTR201812717126560Dermatology department20
进行中（未招募）
1 期
A Phase III Clinical Trial Comparing Docetaxol and Cyclophosphamide (known as the TC chemotherapy regimen) to Doxorubicin, Cyclophosphamide and Docetaxol (known as the TAC chemotherapy regimen) for Women with Node-Positive orHigh-Risk Node-Negative, HER2-Negative Breast CancerAdjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negativeMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021587-15-IEICORG140